Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis

NCT01087762 is registered in ClinicalTrials.gov with UCB BIOSCIENCES GmbH as lead sponsor.

NCT NCT01087762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01087762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis
Lead sponsor
UCB BIOSCIENCES GmbH
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2010
Completion date
August 31, 2015
Enrollment
325 (actual)
Sites
104

Conditions

As the registry lists them; a condition with its own page is linked.

spondyloarthropathies